ASC Site-Selection Intelligence

How it works in practice

Site selection is the highest-stakes analytical decision in de novo ASC development: the location fixes the surgeon pool the center can draw from, the competitors it faces, the payers it will contract with, and the referral patterns it must join or build. Site-selection intelligence brings those factors into one comparative view, so candidate markets can be screened against each other on evidence — provider density, existing ASC competition, specialty demand, and payer context — before capital is committed to any of them.

The practical workflow runs from wide to narrow. A development team starts with a broad region, ranks candidate markets on surgeon supply and competitive saturation, and then examines the shortlist in depth: which specialties are underserved, which facilities would compete for the same cases, and whether the local payer landscape supports the intended case mix. State-level rules such as certificate-of-need requirements shape what is feasible and belong in the screen early. Data narrows the field; it does not replace local diligence — real-estate, regulatory, and physician-partnership work on the ground decides the final site.

What it helps teams do

• Compare provider density and existing ASC competition.
• Review payer and procedure context before choosing a market.
• Support de novo feasibility work without replacing local diligence.

Frequently asked questions

What factors matter most in ASC site selection?

Surgeon supply in the target specialties, the density and case mix of existing ASC competition, local demand for the intended service lines, the payer environment, and state-level regulatory constraints such as certificate-of-need rules. A viable site needs all of them to line up, not just one.

Can market data replace local feasibility work?

No. Market evidence is for screening — ranking candidate markets and eliminating weak ones early. The final decision still depends on local diligence: real-estate specifics, regulatory approvals, payer conversations, and committed physician partners.